BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16445664)

  • 21. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
    Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Peschos D; Goussia A; Mittari E; Charalabopoulos K; Michael M; Salmas M; Vougiouklakis T; Assimakopoulos D; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Jun; 23(2):277-83. PubMed ID: 15354413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
    Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clear Cell Lesions of the Mullerian System: Not Always That "Clear"!
    Wawire J; Lawrence WD; Quddus MR
    Int J Surg Pathol; 2019 Dec; 27(8):884-886. PubMed ID: 30917732
    [No Abstract]   [Full Text] [Related]  

  • 28. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
    Ozuysal S; Oztürk H; Bilgin T; Filiz G
    Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
    Matsuo Y; Tashiro H; Yanai H; Moriya T; Katabuchi H
    Med Mol Morphol; 2015 Sep; 48(3):146-54. PubMed ID: 25398420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
    Shevra CR; Ghosh A; Kumar M
    J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease.
    Shiohara S; Shiozawa T; Miyamoto T; Feng YZ; Kashima H; Kurai M; Suzuki A; Konishi I
    Virchows Arch; 2005 Jun; 446(6):626-33. PubMed ID: 15891905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
    Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
    Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panel of Villin, Pro-Ex-C, Estrogen Receptor and Progesterone Receptor Expressions Could Help in Differentiation Between Endocervical and Endometrioid Adenocarcinoma.
    Elfeky M; Harb O; Gertallah L
    Turk Patoloji Derg; 2017; 1(1):29-40. PubMed ID: 28832070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined expression of p161NK4a and p27Kip1, but not p21WAF1, differentiates endocervical from endometrial adenocarcinoma.
    Abu Backer FM; Mustapha NR; Othman NH
    Anal Quant Cytol Histol; 2011 Oct; 33(5):283-8. PubMed ID: 22611756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
    Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
    Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer.
    Demir L; Ekinci N; Erten C; Somali I; Can A; Dirican A; Cokmert S; Bayoglu V; Akyol M; Kucukzeybek Y; Alacacioglu A; Tarhan MO
    J Surg Oncol; 2014 Jun; 109(7):665-75. PubMed ID: 24464927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.